Kuros Biosciences AG (CSBTF)
Kuros Biosciences AG operates in the Biotechnology industry of the Healthcare sector, headquartered in Schlieren, ZH, CH. The stock last traded at $29.62, up 0.00% on the session, giving a market capitalisation of $1.17B. On trailing twelve-month figures it carries a trailing P/E of 539.91, a net margin of 1.3%. Its beta of 0.76 implies it has historically moved less than the broad market.
Kuros Biosciences AG, a biopharmaceutical firm headquartered in Schlieren, Switzerland, specializes in both bringing to market and advancing therapeutic solutions for tissue repair and bone regeneration. Its global reach extends across the United States, the European Union, and other international markets, with operations strategically divided into Medical Devices, Pharmaceuticals, and a Legacy Portfolio. The company's innovative product lineup includes several key orthobiologics. Their MagnetOs Granules and MagnetOs Putty are already available in the EU and US, serving applications in orthopedics, spinal procedures, and dentistry. Additionally, their fibrin/PTH orthobiologics portfolio features KUR-111, which has successfully concluded Phase 2b clinical trials for treating tibial plateau fractures, and KUR-113, which completed Phase 2b trials for tibial shaft fractures and is currently in Phase II development for spinal interbody fusion. Beyond bone healing, Kuros Biosciences provides advanced sealant solutions, such as Neuroseal, a synthetic tissue sealant approved in the EU and US for preventing cerebrospinal fluid leakage after cranial or spinal surgeries. The company also fosters external partnerships, notably collaborating with Checkmate Pharmaceuticals LLC on the development of CYT003, an oncology treatment.
Kuros Biosciences AG is most often compared with the following Healthcare names: